PARIS - ExonHit Therapeutics SA became the first French biotechnology company in six years to earn a stock exchange listing. (BioWorld International)

PARIS - IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. (BioWorld International)

PARIS - IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. (BioWorld International)

PARIS - ExonHit Therapeutics SA launched an initial public offering on the Alternext market of the Euronext stock exchange in Paris Nov. 8, hoping to raise 6.5 million (US$7.6 million). (BioWorld International)

PARIS - ExonHit Therapeutics SA launched an initial public offering on the Alternext market of the Euronext stock exchange in Paris Nov. 8, hoping to raise 6.5 million (US$7.6 million). (BioWorld International)

PARIS - ExonHit Therapeutics SA and BioMérieux extended and expanded their research collaboration for developing new blood-based diagnostics for the early detection of cancers. (BioWorld International)